586.48
前日終値:
$591.20
開ける:
$581.94
24時間の取引高:
402.48K
Relative Volume:
0.72
時価総額:
$25.15B
収益:
$3.17B
当期純損益:
$1.29B
株価収益率:
21.65
EPS:
27.0947
ネットキャッシュフロー:
$1.01B
1週間 パフォーマンス:
+4.08%
1か月 パフォーマンス:
+20.79%
6か月 パフォーマンス:
+3.05%
1年 パフォーマンス:
+41.20%
United Therapeutics Corp Stock (UTHR) Company Profile
名前
United Therapeutics Corp
セクター
電話
(301) 608-9292
住所
1000 SPRING ST, SILVER SPRING, MD
Compare UTHR vs TAK, TEVA, HLN, ZTS
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
UTHR
United Therapeutics Corp
|
586.48 | 25.15B | 3.17B | 1.29B | 1.01B | 27.09 |
|
TAK
Takeda Pharmaceutical Co Adr
|
20.15 | 64.37B | 29.91B | 1.30B | 3.49B | 0.4056 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
39.97 | 46.62B | 17.53B | 1.58B | 444.18M | 1.3457 |
|
HLN
Haleon Plc Adr
|
10.00 | 43.98B | 14.54B | 2.22B | 2.58B | 0.4871 |
|
ZTS
Zoetis Inc
|
77.80 | 32.15B | 9.51B | 2.64B | 2.14B | 6.0361 |
United Therapeutics Corp Stock (UTHR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-10-01 | アップグレード | BTIG Research | Neutral → Buy |
| 2026-09-24 | 開始されました | Goldman | Sell |
| 2026-05-07 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2026-04-10 | 開始されました | Raymond James | Outperform |
| 2025-10-20 | 開始されました | Wells Fargo | Underweight |
| 2025-09-26 | 開始されました | RBC Capital Mkts | Outperform |
| 2025-06-02 | 開始されました | Cantor Fitzgerald | Overweight |
| 2025-04-25 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2025-04-21 | アップグレード | BofA Securities | Underperform → Neutral |
| 2024-07-11 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2024-02-12 | アップグレード | Goldman | Sell → Neutral |
| 2024-02-05 | 開始されました | Leerink Partners | Outperform |
| 2023-12-08 | 開始されました | Wells Fargo | Overweight |
| 2022-12-06 | 開始されました | UBS | Buy |
| 2022-12-05 | 開始されました | Goldman | Sell |
| 2022-10-11 | 開始されました | Morgan Stanley | Overweight |
| 2022-09-20 | 繰り返されました | BofA Securities | Underperform |
| 2022-09-19 | 再開されました | Wedbush | Outperform |
| 2022-02-11 | 開始されました | BTIG Research | Neutral |
| 2021-07-14 | アップグレード | Argus | Hold → Buy |
| 2021-04-26 | 再開されました | Credit Suisse | Outperform |
| 2021-02-01 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2020-09-14 | 再開されました | JP Morgan | Overweight |
| 2020-06-25 | 繰り返されました | H.C. Wainwright | Neutral |
| 2020-03-10 | アップグレード | Jefferies | Hold → Buy |
| 2020-02-27 | アップグレード | Cowen | Market Perform → Outperform |
| 2020-01-31 | アップグレード | JP Morgan | Neutral → Overweight |
| 2019-12-03 | 開始されました | BofA/Merrill | Underperform |
| 2019-08-01 | アップグレード | Jefferies | Underperform → Hold |
| 2019-08-01 | アップグレード | Ladenburg Thalmann | Neutral → Buy |
| 2019-07-01 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2019-05-17 | アップグレード | UBS | Sell → Neutral |
| 2019-05-09 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2018-10-12 | アップグレード | Standpoint Research | Hold → Buy |
| 2018-08-08 | ダウングレード | Credit Suisse | Neutral → Underperform |
| 2018-04-03 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2018-02-22 | 繰り返されました | Barclays | Underweight |
| 2018-01-18 | 再開されました | Credit Suisse | Underperform |
| 2017-12-27 | 繰り返されました | Wedbush | Outperform |
| 2017-04-27 | 繰り返されました | Wedbush | Outperform |
| 2017-03-30 | 開始されました | UBS | Sell |
| 2017-03-16 | 開始されました | Credit Suisse | Underperform |
すべてを表示
United Therapeutics Corp (UTHR) 最新ニュース
Options exercised at $117.76 a share accompanied sales by United Therapeutics (UTHR) CEO's trusts. - Stock Titan
$100 Invested In United Therapeutics 15 Years Ago Would Be Worth This Much Today - Benzinga
United Therapeutics Rising Ahead of Next Earnings Report - FXEmpire
FDA clears United Therapeutics to begin Treprostinil-Iloprost trial - StreetInsider
CEO trusts exercised $117.76 options and sold 9,500 shares in United Therapeutics (UTHR). - Stock Titan
S&P 500 Futures Up in Premarket Trading; MSG Sports, United Therapeutics Lag - Barron's
United Therapeutics CEO sells $5.5M in stock By Investing.com - Investing.com Nigeria
Form 4 United Therapeutics Corporation: Martine A. Rothblatt (Director, Chairperson & CEO) For: 23 October - Investing.com Nigeria
United Therapeutics CEO sells $5.5M in stock - Investing.com
After exercising options at $117.76, United Therapeutics (UTHR) CEO trusts sell 9,500 shares. - Stock Titan
United Therapeutics (NDQ:UNTR): The Only Company Attempting Xenotransplantation At Scale! - Stocks Down Under
U.S. transgender billionaire Martine Rothblatt sells $5.5 million in United Therapeutics stock - Billionaires.Africa
Martine Rothblatt, United Therapeutics CEO, sells $5.5M in stock - Investing.com
United Therapeutics Gets FDA Clearance to Start Phase 2 SUMMIT Trial of Treprostinil Soft Mist Inhaler in PH-COPD - BioBuzz
United Therapeutics to build a $9 million hangar at Rochester's airport - Post Bulletin
United Therapeutics CEO Rothblatt sells $5.3m in UTHR stock - Investing.com
Is United Therapeutics Corp (UTHR) Overvalued After 3.8% Rally? - GuruFocus
Generation Park lands new facility to scale xeno-organ production - InnovationMap
United Therapeutics authorizes $2 billion buyback program - Investing.com
United Therapeutics Authorizes Up to $2 Billion Share Repurchase - TradingView
United Therapeutics Corporation Announces Additional $2 Billion Share Repurchase Authorization - Yahoo Finance
United Therapeutics CEO Martine Rothblatt sells $5.26m in stock - Investing.com
CEO trusts sell 9,500 United Therapeutics (UTHR) shares after exercising stock options. - Stock Titan
United Therapeutics Corporation to Report Third Quarter 2026 Financial Results Before Market Open on Wednesday, November 4, 2026 - Yahoo Finance
Form 4 United Therapeutics Corporation: Martine A. Rothblatt (Director, Chairperson & CEO) For: 19 October - Investing.com Nigeria
United Therapeutics CEO Rothblatt sells $5.16m in shares - Investing.com
United Therapeutics (UTHR): Can the Profit-Machine Biotech Finally Crack the S&P 500? - Yahoo Finance
United Therapeutics opens third xenograft production facility - Investing.com
A Houston site is built to make pig kidneys and hearts for United Therapeutics’ organ program. - Stock Titan
United Therapeutics opens xeno-organ facility in Generation Park, marking Houston's continued pharma growth - The Business Journals
United Therapeutics Expands Organ Manufacturing Capabilities with Opening of Third Designated Pathogen-Free Xenograft Production Facility - Yahoo Finance
United Therapeutics chairperson & CEO sells $5.08m in shares By Investing.com - Investing.com Nigeria
Form 4 United Therapeutics Corporation: Martine A. Rothblatt (Director, Chairperson & CEO) For: 16 October - Investing.com Nigeria
After exercising options at $117.76, CEO trust sells 9,500 United Therapeutics (UTHR) shares. - Stock Titan
Here’s How Much You Would Have Made Owning United Therapeutics Stock In The Last 5 Years - Benzinga
Here’s How Much You Would Have Made Owning United Therapeutics Stock In The Last 5 Years - Benzinga
United Therapeutics (UTHR) Gains FDA Approval for SUMMIT Trial o - GuruFocus
Up to 800,000 people have high blood pressure in the lungs linked to chronic lung disease. An inhaler trial can proceed. - Stock Titan
United Therapeutics (NASDAQ:UTHR): A GARP Case Built on Durable Growth at a Reasonable Price - ChartMill
United Therapeutics chairperson & CEO sells $5.19m in stock - Investing.com
Paul Mahon, United Therapeutics EVP, sells $4.5m in stock - Investing.com
After exercising options at $117.76 each, CEO trust sells 9,500 United Therapeutics (UTHR) shares. - Stock Titan
An 8,300-share planned sale follows an option exercise by United Therapeutics (UTHR) counsel. - Stock Titan
United Therapeutics CEO Rothblatt sells $5.1m in shares By Investing.com - Investing.com Nigeria
After exercising options at $117.76, United Therapeutics (UTHR) CEO family trusts sell 9,500 shares. - Stock Titan
A CEO trust exercises options at $117.76 and sells 9,500 United Therapeutics (UTHR) shares. - Stock Titan
United Therapeutics secures $381M settlement in patent dispute with competitor - The Business Journals
LQDA Settles UTHR Disputes for $380.7M, Limits Yutrepia Label - Zacks Investment Research
Liquidia shares surge 25% as settlement ends United Therapeutics litigation - Yahoo Finance
SGIOY or UTHR: Which Is the Better Value Stock Right Now? - Zacks Investment Research
United Therapeutics Corp (UTHR) 財務データ
収益
当期純利益
現金流量
EPS
United Therapeutics Corp (UTHR) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| ROTHBLATT MARTINE A | Chairperson & CEO |
Oct 27 '26 |
Sale |
587.73 |
9,500 |
5,583,418 |
324,443 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Oct 26 '26 |
Sale |
588.64 |
9,500 |
5,592,095 |
324,443 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Oct 26 '26 |
Option Exercise |
117.76 |
9,500 |
1,118,720 |
333,943 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Oct 23 '26 |
Option Exercise |
117.76 |
9,500 |
1,118,720 |
333,943 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Oct 23 '26 |
Sale |
582.76 |
9,500 |
5,536,235 |
324,443 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Oct 22 '26 |
Option Exercise |
117.76 |
9,500 |
1,118,720 |
333,943 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Oct 22 '26 |
Sale |
583.38 |
9,500 |
5,542,094 |
324,443 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Oct 21 '26 |
Sale |
560.07 |
9,500 |
5,320,681 |
324,443 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Oct 21 '26 |
Option Exercise |
117.76 |
9,500 |
1,118,720 |
333,943 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Oct 20 '26 |
Sale |
553.87 |
9,500 |
5,261,741 |
324,443 |
大文字化:
|
ボリューム (24 時間):